echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Cell: Reveals the molecular mechanism of antiviral immune response in targeted tumors in triple-negative breast cancer

    Cell: Reveals the molecular mechanism of antiviral immune response in targeted tumors in triple-negative breast cancer

    • Last Update: 2021-01-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Researcher Trey Westbrook said: 'We all know that treatments that partially interfere with RNA shearing may have a significant impact on tumor growth and progression, but the mechanisms behind the tumor's lethal effects are not yet clear to researchers; sub, which usually loses regulation in the tumor, causes the tumor to grow and promotes the tumor to become highly sensitive to sputum targeted therapy (STTs, spliceosome-targeted therapies), one of the malignant cancers that is very sensitive to STTs.
    the study, researchers wanted to understand the molecular mechanisms by which these drugs interfere with tumor progression, and they found in triple-negative breast cancer cells that STTs can interfere with RNA shearing and promote the constant flow of endogenetic miscollaged endogenescity in tumor cell cytones. Accumulate, and many of these abnormal RNAs form a double-stranded structure, as if it were an RNA virus; antiviral immune pathps recognize double-stranded RNA, which then induces apoptosis and sends signals to the body's immune system to induce inflammatory reactions. 'Our study reveals a new way to activate the body's inflammatory response by specifically targeting cancer cells,' said Dr. Elizabeth Bowling,
    .
    Now researchers have a clear understanding of how high levels of false shearing can cause cellular stress in breast cancer cells, and they speculate that RNA shear stress may be present in many cancer types and disease states.
    The study's findings are expected to help researchers find new biomarkers to screen patients who can respond to current immunomodulation therapies, especially if the endogenetic mis stitching of RNA in tumor cells may stimulate the body's immune system, even in the absence of STT therapy, and the data reveal a link between miscratted RNA and immune characteristics, even in immune "cold tumors."
    the researchers speculate that this endologically misshared RNA may be used as a clinical biomarker to find out which cancer becomes sensitive to immunotherapy, and later they need to do more in-depth research to determine whether the activation of the anti-tumor immune path line STTs will make more cancer patients suitable for immunotherapy.
    Finally, researchers say that because immunotherapy still works in a small percentage of cancer patients because of its far-reaching therapeutic effects on certain cancer patients, researchers must learn how to expand the range of patients who can benefit from immunotherapy, and the findings reveal new mechanisms of dialogue between cancer and the immune system that could help develop new strategies to benefit more cancer patients.
    original source: Elizabeth A. Bowling, Jarey H. Wang, Fade Gong, et al. Spliceosome-targeted therapies trigger an antiviral immune response in triple-negative breast cancer, Cell (2021). DOI:10.1016/j.cell.2020.12.031
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.